PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
5.42%
Cash & equivalents yoy growth at least 1.5x the Medical - Pharmaceuticals median of 2.49%. Joel Greenblatt might see strong liquidity accumulation as an advantage. Check if management invests or just hoards cash.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
5.42%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.27%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
-4.73%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
58.31%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
0.82%
1.25-1.5x the Medical - Pharmaceuticals median of 0.60%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
8.40%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.58%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-3.73%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-3.73%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
46.93%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
5.29%
≥ 1.5x the Medical - Pharmaceuticals median of 0.26%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
2.98%
≥ 1.5x the Medical - Pharmaceuticals median of 0.78%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
1.36%
Payables growth below half of Medical - Pharmaceuticals median of 2.87%. Joel Greenblatt sees more conservative payables management vs. peers.
-1.03%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-61.89%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-73.52%
≥ 1.5x the Medical - Pharmaceuticals median of -0.28%. Joel Greenblatt sees a robust subscription base vs. peers.
163.11%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
1.88%
Above 1.5x Medical - Pharmaceuticals median of 0.87%. Jim Chanos suspects potential working capital strain.
-12.64%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
309.95%
Above 1.5x Medical - Pharmaceuticals median of 2.37%. Jim Chanos sees a potentially alarming surge in other LT obligations.
5.41%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
2.41%
Below half Medical - Pharmaceuticals median of -0.91%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
6.37%
≥ 1.5x Medical - Pharmaceuticals median of 0.17%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.13%
≥ 1.5x Medical - Pharmaceuticals median of 1.00%. Joel Greenblatt sees stronger equity growth vs. peers.
2.98%
≥ 1.5x Medical - Pharmaceuticals median of 0.78%. Joel Greenblatt sees more aggressive expansions than peers.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-24.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-52.49%
Above 1.5x Medical - Pharmaceuticals median -0.72%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.